Drug Pricing

Business & Economics

It’s Generics Not PBMs That Keep Pharmaceuticals Affordable

Expenditures on prescription drugs grew 12.4 percent in 2014 and 8.9 percent in 2015. These eye-popping data are not representative of the long-term expenditure trend, however. Not only did the growth in prescription drugs expenditures slow to 1.3 percent in 2016, longer-term (between 2009 and 2016), the average annual growth
Commentary

Canadian Pharmacy Scandal Reveals The Dangers of Drug Importation

A U.S. district court in Montana just imposed a $34 million fine on Canada Drugs, an online pharmacy charged with selling counterfeit medications to unsuspecting Americans. Some of the drugs contained no active ingredients. Canada Drugs isn’t the only online pharmacy that puts patients’ lives in serious jeopardy. The National
Blog

When the Public Option Is the Only Option

Single-payer has failed abroad and at home. Yet the call for single-payer from progressives has never been louder. Vermont senator Bernie Sanders (I-VT) and his dedicated followers have been the loudest. In his campaign for the Democratic presidential nomination in 2016, he promised “Medicare for All.” In September 2017, he
Commentary

Trump’s Drug Pricing Speech Mostly Hit the Right Notes

Last Friday, President Trump delivered a major speech from the White House Rose Garden on prescription drug prices. He announced several policies aimed at reducing the overall cost of pharmaceuticals and limiting patients’ out-of-pocket expenses. His reform agenda, entitled “American Patients First,” is largely excellent. It mostly harnesses the power
Business & Economics

Pharmaceutical Price Controls Will Not Improve Health Care Outcomes in Illinois

Due to its national implications, last week’s introduction of the Department of Health and Human Services’ (HHS) blueprint on drug prices is garnering all the attention. Despite its importance, HHS’ blueprint should not overshadow the many poor, and even unconstitutional, policy proposals that are occurring at the state level.  For
Business & Economics

Creating an Affordable Health Care System Requires More than Rounding Up the Usual Suspects

Health care is becoming less affordable every year. Over the past 10 years, national healthcare expenditures have grown 45 percent, but our economy has grown only 28 percent. This isn’t sustainable; and, solving this problem should be a top policy priority. However, “rounding up the usual suspects,” as Captain Renault
Commentary

Just Say No to Drug Imports

A U.S. district court in Montana just imposed a $34 million fine on Canada Drugs, an online pharmacy charged with selling counterfeit medications to unsuspecting Americans. Some of the drugs contained no active ingredients. Canada Drugs isn’t the only online pharmacy that puts patients’ lives in serious jeopardy. The National Association
Blog

Single-Payer in California: Slowly, Slowly, Catchy Monkey

For now, California’s progressive politicians have judged single-payer as a bridge too far.  But that doesn’t mean they’ve given up trying to take over health care. As my Canadian mother used to say, “slowly, slowly, catchy monkey” – or be patient. On March 14, Assembly lawmakers released a report by
Business & Economics

Report Slams 340B Drug Discount Program

By Tracey Walker The 340B Drug Discount program, designed to give discounted prescription drugs to poor Americans, has not been effective in serving its targeted population, according to a new report. The report, “Addressing the Problems of Abuse in the 340B Drug Pricing Program,” by the Pacific Research Institute, found that the
Commentary

Trump Already Making Progress on Making Prescription Drugs Affordable

During Tuesday’s State of the Union address, President Trump pledged to drive down drug prices. That’s a worthy goal. And fortunately, the Trump administration is already pursuing it in a way that protects patients and encourages research and development. Many of the strategies that candidate Trump proposed on the campaign
Business & Economics

It’s Generics Not PBMs That Keep Pharmaceuticals Affordable

Expenditures on prescription drugs grew 12.4 percent in 2014 and 8.9 percent in 2015. These eye-popping data are not representative of the long-term expenditure trend, however. Not only did the growth in prescription drugs expenditures slow to 1.3 percent in 2016, longer-term (between 2009 and 2016), the average annual growth
Commentary

Canadian Pharmacy Scandal Reveals The Dangers of Drug Importation

A U.S. district court in Montana just imposed a $34 million fine on Canada Drugs, an online pharmacy charged with selling counterfeit medications to unsuspecting Americans. Some of the drugs contained no active ingredients. Canada Drugs isn’t the only online pharmacy that puts patients’ lives in serious jeopardy. The National
Blog

When the Public Option Is the Only Option

Single-payer has failed abroad and at home. Yet the call for single-payer from progressives has never been louder. Vermont senator Bernie Sanders (I-VT) and his dedicated followers have been the loudest. In his campaign for the Democratic presidential nomination in 2016, he promised “Medicare for All.” In September 2017, he
Commentary

Trump’s Drug Pricing Speech Mostly Hit the Right Notes

Last Friday, President Trump delivered a major speech from the White House Rose Garden on prescription drug prices. He announced several policies aimed at reducing the overall cost of pharmaceuticals and limiting patients’ out-of-pocket expenses. His reform agenda, entitled “American Patients First,” is largely excellent. It mostly harnesses the power
Business & Economics

Pharmaceutical Price Controls Will Not Improve Health Care Outcomes in Illinois

Due to its national implications, last week’s introduction of the Department of Health and Human Services’ (HHS) blueprint on drug prices is garnering all the attention. Despite its importance, HHS’ blueprint should not overshadow the many poor, and even unconstitutional, policy proposals that are occurring at the state level.  For
Business & Economics

Creating an Affordable Health Care System Requires More than Rounding Up the Usual Suspects

Health care is becoming less affordable every year. Over the past 10 years, national healthcare expenditures have grown 45 percent, but our economy has grown only 28 percent. This isn’t sustainable; and, solving this problem should be a top policy priority. However, “rounding up the usual suspects,” as Captain Renault
Commentary

Just Say No to Drug Imports

A U.S. district court in Montana just imposed a $34 million fine on Canada Drugs, an online pharmacy charged with selling counterfeit medications to unsuspecting Americans. Some of the drugs contained no active ingredients. Canada Drugs isn’t the only online pharmacy that puts patients’ lives in serious jeopardy. The National Association
Blog

Single-Payer in California: Slowly, Slowly, Catchy Monkey

For now, California’s progressive politicians have judged single-payer as a bridge too far.  But that doesn’t mean they’ve given up trying to take over health care. As my Canadian mother used to say, “slowly, slowly, catchy monkey” – or be patient. On March 14, Assembly lawmakers released a report by
Business & Economics

Report Slams 340B Drug Discount Program

By Tracey Walker The 340B Drug Discount program, designed to give discounted prescription drugs to poor Americans, has not been effective in serving its targeted population, according to a new report. The report, “Addressing the Problems of Abuse in the 340B Drug Pricing Program,” by the Pacific Research Institute, found that the
Commentary

Trump Already Making Progress on Making Prescription Drugs Affordable

During Tuesday’s State of the Union address, President Trump pledged to drive down drug prices. That’s a worthy goal. And fortunately, the Trump administration is already pursuing it in a way that protects patients and encourages research and development. Many of the strategies that candidate Trump proposed on the campaign
Scroll to Top